Developed in the same halls where CRISPR was created, CatenaBio’s technology enables the fusion of proteins with the 3-dimensional control that only previously existed with small molecule synthesis. The result is the ability to synthesize novel biomolecules in any structure, combination, or orientation—the only limitation is imagination.
We foresee the impact of our bioconjugation approach extending across therapeutic areas; it may even have consumer applications.
The core of CatenaBio’s technology results from an exhaustive search of the microbial kingdom for a robust enzyme with broad effectiveness. The patented Catenase® technology enables biomolecules to be fused at naturally occurring amino acids—tyrosine and cysteine—under gentle reaction conditions that optimize novel biomolecule yield.
Originating From Berkeley Labs
Our science is invented by the top minds at UC Berkeley